Publications by authors named "Roseanne Vliegenthart"
Article Synopsis
- The study aimed to investigate how the severity of bronchopulmonary dysplasia (BPD) affects the risk of neurodevelopmental impairment (NDI) at ages 2 and 5 years, and whether this relationship changes over time.
- Involving 790 infants born before 30 weeks of gestation, the findings showed that those with varying degrees of BPD had a significantly higher risk of NDI compared to infants without BPD, with a marked increase in NDI risk from age 2 to age 5.
- The research concluded that greater BPD severity correlates with higher NDI risk at both ages, and while the incidence of NDI increased from 2 to 5 years,
Electrical impedance tomography (EIT) allows instantaneous and continuous visualization of regional ventilation and changes in end-expiratory lung volume at the bedside. There is particular interest in using EIT for monitoring in critically ill neonates and young children with respiratory failure. Previous studies have focused only on short-term monitoring in small populations.
View Article and Find Full Text PDFBackground And Objective: Restrictive use of invasive mechanical ventilation (IMV) in preterm infants reduces the risk of bronchopulmonary dysplasia (BPD). Our objective was to determine its effect on neurodevelopmental impairment (NDI) at 24 months' corrected age (CA).
Methods: This retrospective single-center cohort study included all patients with a gestational age <30 weeks born in 2004/2005 (epoch 1) and 2010/2011 (epoch 2).
Background: Apnea of prematurity (AOP) is a common complication of preterm birth, for which caffeine is the first treatment of choice. In case of persistent AOP, doxapram has been advocated as an additional therapy.
Objective: To identify and appraise all existing evidence regarding efficacy and safety of doxapram use for AOP in infants born before 34 weeks of gestational age.
Background: Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP).
Objective: To evaluate the effect of doxapram on long-term neurodevelopmental outcome in preterm infants as its safety still needs to be established.
Methods: From a retrospective cohort of preterm infants with a gestational age (GA) <30 weeks and/or a birth weight <1,250 g, born between 2000 and 2010, infants treated with doxapram (n = 142) and a nontreated control group were selected (n = 284).